insights_auto
Why is LSTA down 4,59%?
Dive Deeperchevron_right
LSTA:NASDAQ
Lisata Therapeutics, Inc.
1,04 $
arrow_downward
-4,59%(-0,050) 1D
17 նոյ, 16:00:01 GMT-5 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for LSTA...
Open
1,08 $
High
1,10 $
Low
1,00 $
Mkt. cap
11,24 մլն
Avg. vol.
135,12 հզր
Volume
0,00
52-wk high
5,06 $
52-wk low
0,96 $
EPS
-1,64 $
Beta
1,04
Shares outstanding
10,80 մլն
No. of employees
21
Open
1,08 $
High
1,10 $
Low
1,00 $
Mkt. cap
11,24 մլն
Avg. vol.
135,12 հզր
Volume
0,00
52-wk high
5,06 $
52-wk low
0,96 $
EPS
-1,64 $
Beta
1,04
Shares outstanding
10,80 մլն
No. of employees
21
News stories
From web sources and news partners
FOREX.com
·
25 րոպե առաջ
S&P 500 Quietly Shrugs Off the Bitcoin and Silver Selloff
Reuters
·
29 րոպե առաջ
UBS sees S&P 500 at 8,200 by end-2027 on earnings strength, resilient economy
BeInCrypto
·
2 ժամ առաջ
How Deep Do S&P 500 Corrections Usually Go? Where 2026’s Drop Ranks
Profile
Lisata Therapeutics is an American clinical stage pharmaceutical company active in the field of oncology, specifically aimed at developing and commercializing new cancer therapies. It was formed through a merger of Cend Therapeutics and Caladrius Biosciences in September 2022.
In 2019, the FDA granted their product, certepetide, orphan drug status in pancreatic cancer, followed by a Fast track status in 2022. Non-clinical data collected by Lisata and others have demonstrated enhanced delivery of various existing and emerging anti-cancer therapies, including chemotherapies, immunotherapies and RNA-based therapeutics when used with certepetide. Wikipedia
About Lisata Therapeutics, Inc.
CEO-
Employees21
Founded1980
HeadquartersBasking Ridge, Նյու Ջերսի, Միացյալ Նահանգներ
SectorHealth Care
Industry-
Websitelisata.com